The future of comprehensive cancer care
Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.
“tests like these assure patients get the best cancer care, as clinicians use these results to determine the best treatment strategies based on the patients tumor profile - It's really that simple.”
Benjamin Kipp, Ph.D., chair of the Division of Laboratory Genetics and Genomics
Our difference
News and updates
The latest
Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.
In this “Hot Topic,” Joshua Bornhorst, Ph.D., assistant professor of laboratory medicine and pathology at Mayo Clinic, reviews biomarker component testing for hepatocellular carcinoma, explains the GALAD score, and explores GALAD score testing at Mayo Clinic Laboratories.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.
It’s been more than three years since a team of specialists and genetic testing by Mayo Clinic Laboratories helped pinpoint the cause of Alexa Lofaro’s failing health. And today, she says she continues to feel “so much better” than she did when she first came to Mayo Clinic.
This week's Research Roundup feature: A stress-induced cilium-to-PML-NB route drives senescence initiation.
As someone affected by chronic liver disease, Susan Parrott knows how it feels to live in uncertainty. But every few months, the anxiety and doubt that shadow her life fade when Mayo Clinic Laboratories test results confirm her condition is in check and she can continue living life on her own terms.
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
After what looked like a blemish turned out to be angiosarcoma, a rare, life-threatening cancer of the blood vessels, Alison O'Neill was put on an aggressive treatment plan and regenerative approach to healing made possible by the pathologist who first diagnosed her cancer.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
For Billy Dowell Jr., a competitive golfer, focus, determination, and course correction are essential to excelling at the sport. These skills, along with routine follow-up care and testing, are also important to navigating a life impacted by multiple chronic autoimmune conditions.
Steven Ansell, M.D., Ph.D., chair of the Division of Hematology and senior deputy director, Midwest, Mayo Clinic Comprehensive Cancer Center, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D., about declining cancer death rates. In this episode, Dr. Ansell and Dr. Pritt discuss advancements in cancer treatments that are leading to declining death rates, the role diagnostics plays in cancer treatment, and what the future may hold for cancer diagnostics.
As part of Mayo Clinic’s Neuro-Oncology practice, the Division of Laboratory Genetics and Genomics tests about 50 brain tumors a week, and upwards of 1,500 brain tumors a year from all over the world.